Investors Overview

About Us

Bioblast Pharma is a publicly traded, clinical-stage biotechnology company (NASDAQ - "ORPN") committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.

Our therapeutic platforms are based on deep understanding of the disease-causing biological processes, and can potentially offer solutions for several diseases that share the same biological pathology.

Given the interest in the scientific and medical community regarding alternative therapeutic uses of our lead drug candidate, trehalose 90mg/mL IV solution, Bioblast has decided to postpone work on our other therapeutic platforms and to concentrate internal development efforts exclusively on trehalose.

The company is led by a management team experienced in the development and commercialization of disease therapeutics.

Read More


There are currently no events scheduled.

More Events


Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial ResultsFebruary 24, 2017
TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today annou... 
Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative DiseasesFebruary 01, 2017
Investor Lunch and Live Webcast at 12 noon Eastern Time Tomorrow TEL AVIV, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clini... 
Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2January 26, 2017
Investor Lunch and Live Webcast at 12 Noon Eastern Time on February 2 TEL AVIV, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a cl... 
More News